Assertio Holdings (ASRT) unusual buy of 1500 ITM September $2 calls at $1.40 offers with a wide bid/ask spread. The $141M small cap drug name is near a break out of a tight weekly range above 3.25. Recently BWS Financial initiated coverage with a Buy rating and $6 price target. The “classic roll-up story” has managed to stay under investor radars while acquiring drugs with small revenue streams, but those revenues are starting to add up and should have a positive impact to the stock price while the company can use its digital marketing approach to grow earnings and free cash flow.